Skip to main content
Guy Tillinghast, MD, Oncology, Mentor, OH, University Hospitals Cleveland Medical Center

GuyW.TillinghastMD

Oncology Mentor, OH

Physician

Dr. Tillinghast is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tillinghast's full profile

Already have an account?

  • Office

    Lake Health UH Seidman Cancer Center
    9485 Mentor Ave Ste 3
    Mentor, OH 44060
    Phone+1 440-205-5755
    Fax+1 440-205-5759
  • Is this information wrong?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
  • UMass Chan Medical School
    UMass Chan Medical SchoolResidency, Internal Medicine, 1992 - 1995
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 1992
  • Brown University
    Brown UniversityPre-med, 1985 - 1988
  • Brown University
    Brown UniversityA.B., Honors English, 1982
  • Portsmouth Abbey School
    Portsmouth Abbey SchoolDiploma, 1976

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2001 - 2026
  • DE State Medical License
    DE State Medical License 2019 - 2023
  • PA State Medical License
    PA State Medical License 2020 - 2022
  • ME State Medical License
    ME State Medical License 2017 - 2021
  • VA State Medical License
    VA State Medical License 2001 - 2018
  • MN State Medical License
    MN State Medical License 2017 - 2018
  • Join now to see all

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
  • Post-Fellowship Training Award National Cancer Institute, 1998
  • High Distinction in Biology 11, 12 Post-Baccalaureate study, Brown University

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase II Study of Gemcitabine and Bevacizumab as First-line Treatment in Taxane-pretreated, HER2-negative, Locally Recurrent or Metastatic Breast Cancer  
    Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg..., Clin Breast Cancer, 1/1/2012
  • Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/everolimus as First-line Treatment for Patients with Glioblastoma  
    Hainsworth JD, Shih KC, Shepard GC, Tillinghast GW, Brinker BT, Spigel DR, Clin Adv Hematol Oncol, 1/1/2012
  • PPARg Expression Correlates with Differentiated Colon Tumor Lines  
    Tillinghast, G.W. and Segal, S., Proceedings of the American Association for Cancer Research, 1/1/1997

Lectures

  • Cancer Statistics 
    Blackstone, Virginia - 9/14/2004
  • Cancer Management 
    Blackstone, Virginia - 9/14/2004
  • Supportive Care 
    Blackstone, Virginia - 9/14/2004

Press Mentions

  • Appreciation for Beebe’s Excellent Care Leads to Art from the Heart
    Appreciation for Beebe’s Excellent Care Leads to Art from the HeartMarch 30th, 2021

Hospital Affiliations